Patriots' Cannon hits practice field for the first time since diagnosis
Just three months after finishing chemotherapy for non-Hodgkin's lymphoma, New England Patriots rookie Marcus Cannon has started practicing with the team.
Cannon, the 6 foot 6 inch, 348 pound offensive tackle, has not played any football since early January, when he played with TCU against Wisconsin in the Rose Bowl.
"It was awesome, finally getting to play with the team,’’ Cannon told the media at his first practice. “It was finally nice to actually get on and move around a little bit, and have fun a little bit."
Whether or not Cannon will actually see any game time this season remains to be seen, but his progress thus far has impressed fans, players and Patriots executives alike.
"I appreciate the fact he didn’t come out there looking for any kind of pity," said his coach, Bill Belichick. "He’s out there working, and working hard, just like everyone else.’’
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
